Survival with Cemiplimab in Recurrent Cervical Cancer

Overview of attention for article published in New England Journal of Medicine, February 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news: 98 news outlets
blogs: 2 blogs
twitter: 50 X users

facebook: 1 Facebook page
guideline: 9 clinical guideline sources
podcasts: 2 podcasts

Readers on

mendeley: 265 Mendeley

So far, Altmetric has seen 3 posts from 2 blogs.

Cemiplimab treatment of recurrent cervical cancer is associated with longer overall survival

Physician's Weekly, 15 Feb 2022

1. Overall survival is longer in patients treated with cemiplimab as compared to chemotherapy. 2. Fewer adverse effects are…

RCT: Survival with Cemiplimab in recurrent cervical cancer.

SPECIALTIES, 11 Feb 2022

Survival with Cemiplimab in Recurrent Cervical Cancer – New England Journal of Medicine (link to abstract – $ for full-text…

Cemiplimab Prolongs Survival in Recurrent Cervical Cancer

Physician's Weekly, 11 Feb 2022

THURSDAY, Feb. 10, 2022 (HealthDay News) — For patients with recurrent cervical cancer after first-line platinum-containing…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity.